Worth reading
60In focus
Scored from 4 of 6 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
肌の細胞ネットワークを制御する新規生薬抽出物（複数の植物抽出物）
Applicable field (uses covered by this announcement)
肌のホメオスタシス維持、化粧品・皮膚研究
Relationship between the counterparty and the company
IVY COSMETICS CORPORATION4918
CounterpartyJapanese Society of Pharmacognosy
Registration number and expiry date
特許第7455435号（ＮＦ－κＢ／ＪＡＫデュアル阻害剤）
Location (as indicated in this announcement)
Akasaka, Minato-ku, Tokyo (head office)
Impact on Business Performance
At this time, there is no impact on results for the current fiscal year
The company does not address Contract Value / Offering price.
Source (materials cited by the company)
日本生薬学会第71回年会
| Item | Details |
|---|---|
| Names of Products / Services Covered | 肌の細胞ネットワークを制御する新規生薬抽出物（複数の植物抽出物） |
| Counterparty | Japanese Society of Pharmacognosy |
| Applicable area | 肌のホメオスタシス維持、化粧品・皮膚研究 |
| Registration number and expiry date | 特許第7455435号（ＮＦ－κＢ／ＪＡＫデュアル阻害剤） |
| Location | Akasaka, Minato-ku, Tokyo (head office) |
| Impact on Business Performance | At this time, there is no impact on results for the current fiscal year |
| Source | 日本生薬学会第71回年会 |
Items this document does not state (11)
Counterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyLocation scaleQuantitative EffectsUsage history
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.肌のホメオスタシス維持には、単一細胞ではなく、表皮細胞・線維芽細胞・免疫細胞などの細胞ネットワークを多方面から制御することが重要と考え、該当する植物抽出物を探索したため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.